Ardelyx Appoints Mark Kaufmann to Chief Business Officer
News Sep 01, 2011
Ardelyx, Inc. has announced that it has appointed Mr. Kaufmann to the newly created position of Chief Business Officer.
Mr. Kaufmann's role will include business and corporate development, licensing, and strategic planning. Mr. Kaufmann is formerly the CEO of Allostera and Celmed BioSciences.
"Mark's deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development," said Mike Raab, Chairman and CEO of Ardelyx.
Raab continued, "We are excited to have Mark join the team and are looking forward to his leadership in establishing partnerships for Ardelyx as we advance our products."
Mr. Kaufmann has over twenty years of experience in the biopharmaceutical industry in both the U.S. and Canada in business and corporate development roles.
Most recently, Mr. Kaufmann was President and CEO of Allostera Pharma Inc., a venture-backed, preclinical company focused on autoimmune diseases, where he raised $17 million to develop the company's products.
Prior to joining Allostera, Mr. Kaufmann was President and CEO of Celmed BioSciences where he was responsible for raising funds and selling the company in a deal worth over $40M to a European biotechnology company, Kiadis Pharma.
Prior to his role as CEO, he was Chief Operating Officer at Celmed with responsibility for the operations and corporate development of the Company including the progression of Celmed's three products into Phase I/II human clinical testing, the development of a new business plan for Celmed and its early merger with NewBiotics Inc.
Prior to joining Celmed, Mr. Kaufmann was Vice-President Corporate Development at Nexia Biotechnologies Inc. in Montreal where he was responsible for building Nexia's biopharmaceutical business, including product development and licensing agreements.
He was previously Chief Financial Officer of Conceptis Technologies Inc., a medical media and education company, and prior to that, Mr. Kaufmann worked for five years with MedImmune, Inc, located in Maryland, as Director of Planning and Analysis, where he led the strategic planning and contributed to the development of MedImmune's commercialization strategy.
Mr. Kaufmann holds an MBA from the University of Michigan School of Business and a BA in Biochemical Sciences from Harvard University.
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
A computer-guided algorithm may help scientists find just the right spot to split a protein and then reassemble it to functionality, according to a new study. Researchers say this could be another step — perhaps even a dance step — toward using chemical and light signals to create new medical treatments and biosensors.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019